Evelyn A. Reynolds, M.D.

  1. Gynecologic Oncologist
  2. Gynecologist
  1. Capasso I, Cucinella G, Wright DE, Takahashi H, De Vitis LA, Gregory AV, Kim B, Reynolds E, Fumagalli D, Occhiali T, Fought AJ, McGree ME, Packard AT, Causa Andrieu PI, Fanfani F, Scambia G, Langstraat CL, Famuyide A, Breitkopf DM, Mariani A, Glaser GE, Kline TL. Artificial intelligence model for enhancing the accuracy of transvaginal ultrasound in detecting endometrial cancer and endometrial atypical hyperplasia. Int J Gynecol Cancer. 2024 Oct 7; 34 (10):1547-1555 Epub 2024 Oct 07
    View PubMed
  2. Kailasam A, Jatoi A, Reynolds E, Cliby W, Langstraat C. Understanding the patient experience in nonsurgical management of endometrial cancer and complex atypical hyperplasia due to obesity: A qualitative analysis. Gynecol Oncol Rep. 2024 Aug; 54:101425 Epub 2024 May 27
    View PubMed
  3. De Vitis LA, Fumagalli D, Schivardi G, Capasso I, Grcevich L, Multinu F, Cucinella G, Occhiali T, Betella I, Guillot BE, Pappalettera G, Shahi M, Fought AJ, McGree M, Reynolds E, Colombo N, Zanagnolo V, Aletti G, Langstraat C, Mariani A, Glaser G. Incidence of sentinel lymph node metastases in apparent early-stage endometrial cancer: a multicenter observational study. Int J Gynecol Cancer. 2024 May 6; 34 (5):689-696 Epub 2024 May 06
    View PubMed
  4. Fumagalli D, De Vitis LA, Caruso G, Occhiali T, Palmieri E, Guillot BE, Pappalettera G, Langstraat CL, Glaser GE, Reynolds EA, Fruscio R, Landoni F, Mariani A, Grassi T. Low-Volume Metastases in Apparent Early-Stage Endometrial Cancer: Prevalence, Clinical Significance, and Future Perspectives. Cancers (Basel). 2024 Mar 29; 16(7).
    View PubMed
  5. Capasso I, Cucinella G, Volcheck G, McGree M, Fought AJ, Chuzhyk O, De Vitis LA, Schivardi G, Fumagalli D, Occhiali T, Fanfani F, Chiantera V, Scambia G, Reynolds E, Mariani A, Glaser G. Let go of the myth: safety of indocyanine green for sentinel lymph node mapping in endometrial cancer. Int J Gynecol Cancer. 2024 Jan 5; 34 (1):80-87 Epub 2024 Jan 05
    View PubMed
  6. Loomer L, Ward KC, Reynolds EA, von Esenwein SA, Lipscomb J. Racial and socioeconomic disparities in adherence to preventive health services for ovarian cancer survivors. J Cancer Surviv. 2019 Aug; 13 (4):512-522 Epub 2019 June 06
    View PubMed
  7. Wei J, Zhang L, Li J, Zhu S, Tai M, Mason CW, Chapman JA, Reynolds EA, Weiner CP, Zhou HH. MicroRNA-205 promotes cell invasion by repressing TCF21 in human ovarian cancer. J Ovarian Res. 2017 May 5; 10 (1):33 Epub 2017 May 05
    View PubMed
  8. Melancon T, Bivona C, Klenke S, Rockey M, Huh J, Henry D, Grauer D, Al-Kasspooles M, Johnson G, Reynolds E, Chapman J. Comparison of postoperative venous thromboembolism incidence in gastrointestinal and gynecologic solid tumors. Thromb Res. 2016 Nov; 147:104-107 Epub 2016 Oct 06
    View PubMed
  9. Reynolds EA, Tierney K, Keeney GL, Felix JC, Weaver AL, Roman LD, Cliby WA. Analysis of outcomes of microinvasive adenocarcinoma of the uterine cervix by treatment type. Obstet Gynecol. 2010 Nov; 116(5):1150-7.
    View PubMed
  10. Lewis KA, Lilly KK, Reynolds EA, Sullivan WP, Kaufmann SH, Cliby WA. Ataxia telangiectasia and rad3-related kinase contributes to cell cycle arrest and survival after cisplatin but not oxaliplatin. Mol Cancer Ther. 2009 Apr; 8(4):855-63.
    View PubMed
  11. Reynolds EA, DuBeshter B, Katzman P, Larson K, Katzel S, Glantz C. Expression of CD44, E-cadherin, and antimetastatic protein nm23-H1 in complete hydatidiform moles. Gynecol Oncol. 2007 Feb; 104 (2):451-4 Epub 2006 Oct 04
    View PubMed
  12. Reynolds EA, Moller KA. A review and an update on the screening of epithelial ovarian cancer. Curr Probl Cancer. 2006 Sep-Oct; 30 (5):203-32
    View PubMed
  13. Reynolds E, Logani, S , Moller, K , Horowitz, I . Embryonal rhabdomyosarcoma of the uterus in a postmenopausal woman Gynecologic Oncology. 2006; 103, 736-739.